United States
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • CH
    • DK
    • PL
    • UK
  • News
  • US
  • World
  • Business
  • Technology
  • Science
  • Entertainment
  • Sports
  • Health
  • States
  • @
  • Artificial intelligence
  • Arts and design
  • Books
  • Business
  • Celebrities
  • Chicago
  • Computing
  • Dallas
  • Diesel
  • Economy
  • Entertainment
  • Entrepreneurship
  • Environment
  • Fitness
  • Fort Worth
  • Gadgets
  • Gas
  • Genetics
  • Golf
  • Health
  • Health care
  • Houston
  • Internet
  • Jacksonville
  • Jobs
  • Los Angeles
  • Markets
  • Medication
  • Mental health
  • MLB
  • Mobile
  • Movies
  • Music
  • NASCAR
  • NBA
  • NCAA Basketball
  • NCAA Football
  • New York
  • News
  • NFL
  • NHL
  • Nutrition
  • Personal finance
  • Philadelphia
  • Phoenix
  • Physics
  • San Antonio
  • San Diego
  • Science
  • Soccer
  • Space
  • Sports
  • Technology
  • Tennis
  • TV
  • United States
  • US
  • Virtual reality
  • Wildlife
  • WNBA
  • World
United States
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • CH
    • DK
    • PL
    • UK
  • News
  • US
  • World
  • Business
  • Technology
  • Science
  • Entertainment
  • Sports
  • Health
  • States
  • @
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals - Endpoints News
MMental health

Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals – Endpoints News

  • February 17, 2026
  1. Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals  Endpoints News
  2. Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials  Yahoo Finance
  3. Compass says its psilocybin drug helped patients with severe depression in two trials  statnews.com
  4. Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push  Fierce Biotech
  5. Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression  Business Wire
  • Tags:
  • clinical trials
  • Compass Pathways
  • FDA approval
  • Health
  • MADRS scale
  • Mental Health
  • psilocybin
  • psychiatric treatment
  • r&d
  • Treatment-resistant depression
  • United States
  • UnitedStates
  • US
United States
www.europesays.com